Higher doses of α-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma
Authors:
- 1 October 1997
- journal article
- clinical trial
- Published by Elsevier in European Journal of Cancer
- Vol. 33 (11) , 1900-1902
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Combination of chemotherapy and recombinant interferon-alpha in advanced non-small cell lung cancerCancer Letters, 1997
- Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.Journal of Clinical Oncology, 1996
- A phase I trial of 5-day continuous infusion cisplatin and interferon αCancer Chemotherapy and Pharmacology, 1995
- A phase I trial of intermittent high-dose α-interferon and dexamethasone in metastatic renal cell carcinomaAnnals of Oncology, 1995
- A phase I trial of 5-day continuous infusion cisplatin and interferon ?Cancer Chemotherapy and Pharmacology, 1995
- Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer: Multicentric randomized FONICAP trial reportCancer, 1993
- Phase II study of continuous subcutaneous interferon-alfa combined with cisplatin in advanced malignant melanomaEuropean Journal of Cancer, 1992
- A phase I trial of recombinant alpha-2a Interferon (Roferon-A) with weekly cisplatinumInvestigational New Drugs, 1991
- Original article: Potentiation of cisplatin by alpha-Interferon in advanced non-small cell lung cancer (NSCLC): A phase II studyAnnals of Oncology, 1990